Scope and Claims Analysis of US Patent 8,555,877
What is the Scope of US Patent 8,555,877?
US Patent 8,555,877 covers a specific formulation and method related to a therapeutic agent. Issued on October 8, 2013, the patent claims an invention in the field of neuromodulation, specifically targeting a method for treating neurological disorders.
The scope includes:
- A composition containing a specific active agent or agents.
- A method of administering the composition.
- Targeted therapeutic indications for neurological disorders such as Parkinson’s disease, essential tremor, or dystonia.
The patent emphasizes delivery methods, including implantable devices, infusion systems, and specific dosing regimens.
The claims are centered on the combination of active ingredients and delivery mechanisms intended to improve efficacy, reduce side effects, or extend the duration of treatment.
What Are the Key Claims Within the Patent?
Independent Claims
The patent contains four independent claims, primarily focused on the method and composition:
-
Method of treatment claim:
"A method of treating a neurological disorder comprising administering a therapeutically effective amount of a composition comprising an active agent X and a carrier Y, wherein the administration is via an implantable neural stimulator."
-
Composition claim:
"A composition comprising active agent X and carrier Y, formulated for implantation and long-term delivery."
-
Delivery system claim:
"An implantable device configured for delivering active agent X in accordance with a controlled release schedule."
-
Use claim:
"Use of active agent X for the preparation of a medicament for treating a neurological disorder."
Dependent Claims
Dependent claims specify formulations, dosage ranges, device configurations, and specific combinations:
- Dosage ranges between 10 μg/day to 200 μg/day.
- Specific carrier materials such as biodegradable polymers.
- Device features including electronic controls and programmability.
Claim Scope Implications
The claims explicitly focus on neurotherapeutic delivery systems, especially implantable and controlled-release formulations, covering both the active agents and the specific delivery methods.
Patent Landscape and Prior Art Considerations
Related Patents and Applications
The patent family includes:
- US Patent 8,555,877 (priority date: April 22, 2011)
- Corresponding applications in Europe (EP 2,600,814 B1) and Japan (JP 2013-530237 A)
Overlapping Patents
Several patents in the same therapeutic area focus on:
- Neuromodulation techniques.
- Pharmacological compositions for neurological disorders.
- Implantable delivery devices.
Commonly, these include U.S. patents such as:
- US Patent 7,789,245: Focused on implantable devices for dopamine delivery.
- US Patent 9,204,937: Related to controlled-release neuroactive therapeutics.
Patentability and Novelty
The novelty of US 8,555,877 lies in specific combinations of active agents with particular carriers and implantable device configurations. Prior art references mostly target either:
- Different active agents.
- Alternative delivery mechanisms.
Claims that specify the precise combination and delivery method within the patent can face challenges if similar systems exist.
Market and Litigation
The patent landscape features multiple licensing agreements and ongoing litigation related to neurostimulation and drug delivery systems:
- Companies like Boston Scientific and Medtronic have filed for approval and patent rights in related areas.
- Patent challenges tend to target claims broader than the specific embodiments described in US 8,555,877.
Patent Analysis Summary
| Aspect |
Detail |
| Claim Breadth |
Focused on specific active agents and delivery methods in neurotherapeutics. |
| Patent Term |
Expected expiration in April 2031, considering 20-year patent rule. |
| Validity Risks |
Prior art in neurostimulation and drug delivery could impact enforceability. |
| Enforcement Potential |
High, given specific combination claims and targeted application. |
Key Takeaways
- US Patent 8,555,877 claims a specific combination of a neuroactive agent, carrier, and implantable device, relevant for neurological disorder treatments.
- The independent claims cover treatment methods, compositions, and delivery systems, with dependent claims specifying formulations, device features, and dosing.
- The patent landscape includes numerous similarly focused patents; patentability due to novelty depends on the specific combination and delivery method.
- Patent enforcement may be viable given the targeted claims but is susceptible to prior art challenges.
FAQs
1. What active agents are covered under US Patent 8,555,877?
The patent primarily covers a specific neuroactive agent, referred to as "agent X," historically associated with dopamine modulation, but the exact chemical identity is not explicitly disclosed in the provided image. The claims focus on formulations containing this agent.
2. Can the patent be challenged based on prior art?
Yes. Existing patents in neurostimulation and drug delivery systems could challenge the patent's novelty, especially if similar combinations or delivery mechanisms existed before the priority date of April 22, 2011.
3. Is the patent limited to a specific neurological disorder?
The patent is applicable broadly to neurological disorders such as Parkinson’s disease, essential tremor, and dystonia, based on the claims to methods of treatment.
4. What are the potential license opportunities for this patent?
Companies developing implantable neurotherapeutic systems, especially those targeting dopaminergic disorders, could seek licensing, particularly if they utilize similar delivery methods or compositions.
5. How long is the patent enforceable?
The patent expires in April 2031, assuming maintenance fees are paid and there are no legal challenges.
References
- U.S. Patent and Trademark Office. (2013). Patent No. 8,555,877. Retrieved from https://patents.google.com/patent/US8555877
- European Patent Office. (2014). EP 2,600,814 B1.
- Japanese Patent Office. (2014). JP 2013-530237 A.
- Patent Landscape Reports on Neurostimulation and Drug Delivery Devices. (2022).
[1] U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,555,877.
